KRAS peptide vaccine (Sidney Kimmel Cancer Center/Bristol-Myers Squibb)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameKRAS peptide vaccine (Sidney Kimmel Cancer Center/Bristol-Myers Squibb)
Drug Alias Namepooled mutant KRAS-targeted long peptide vaccine (Sidney Kimmel Cancer Center/Bristol-Myers Squibb)
ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSidney Kimmel Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb CompanySidney Kimmel Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A